Canaccord Genuity Maintains Buy on Travere Therapeutics, Raises Price Target to $23
TRAVERE THERAPEUTICS INC -6.85%
TRAVERE THERAPEUTICS INC TVTX | 14.01 | -6.85% |
Canaccord Genuity analyst Edward Nash maintains Travere Therapeutics (NASDAQ:
TVTX) with a Buy and raises the price target from $18 to $23.